LAUSR

mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;16:333–343. 8. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58. 9. Van Hest RM, Mathot RA, Pescovitz MD, et al. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006;17:871–880. 10. Nataraj C, Oliveiro MI, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurindependent pathway. J Clin Invest. 1999; 104:1693–1701. 11. Ward RJ, Abiaka C, Peters TJ. Inflammation and tissue injury: the world of free radicals. J Nephrol. 1994;7:89–95. 12. Wang J, Hu W, Xie H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 2007;16:707–712.